Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HUWE1 | Q7Z6Z7 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14181325 | 0.70 | RECQL (0.67) | HUWE1MAPTALDH1A1NPSR1KDM4E | |
| SCHEMBL168409 | 0.69 | EGFR (0.68) | SMN1; SMN2HTTLMNAHPGDMAPK1 | |
| SCHEMBL6263381 | 0.69 | DRD4 (0.70) | MAPTALDH1A1KDM4ESMN1; SMN2TSHR | |
| SCHEMBL28144851 | 0.68 | PRMT6 (0.56) | HUWE1MAPTALDH1A1KDM4EHTT | |
| SCHEMBL473395 | 0.68 | RECQL (0.54) | HUWE1MAPTALDH1A1NPSR1KDM4E | |
| SCHEMBL4896185 | 0.67 | HRH4 (0.75) | HUWE1MAPTNPSR1KDM4EMAPK1 | |
| SCHEMBL5025315 | 0.66 | HUWE1 (0.49) | HUWE1ALDH1A1SMN1; SMN2ABCC1HTT | |
| SCHEMBL6761398 | 0.66 | MAPT (0.70) | MAPTALDH1A1NPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL8851335 | 0.66 | PDE4A (0.55) | HUWE1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL10659701 | 0.66 | PDE4A (0.50) | HUWE1ALDH1A1SMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843644-A | Preparation method of ubiquitin ligase HUWE1 specific antagonist BI8626 | 烟台皓元生物医药科技有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | claimed |
| CN-117843644-B | Preparation method of ubiquitin ligase HUWE1 specific antagonist BI8626 | 烟台皓元生物医药科技有限公司 | 2026-04-17 | — | — | CN | disclosed |
| CN-117843644-B | Preparation method of ubiquitin ligase HUWE1 specific antagonist BI8626 | 烟台皓元生物医药科技有限公司 | 2026-04-17 | — | — | CN | disclosed |
| CN-117843644-A | Preparation method of ubiquitin ligase HUWE1 specific antagonist BI8626 | 烟台皓元生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843644-A | Preparation method of ubiquitin ligase HUWE1 specific antagonist BI8626 | 烟台皓元生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843644-A | Preparation method of ubiquitin ligase HUWE1 specific antagonist BI8626 | 烟台皓元生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| EP-3943090-A1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | Massachusetts Eye & Ear Infirmary (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | HUWE1 3429/4885MAPT 2956/4885ALDH1A1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.